Recent research using
polymers from www.polyscitech.com
(PolyVivo AK10) have found that encapsulation of chemotherapeutic agents
ABT-737 and camptothecin reduces their side effects as well as induces higher
cancer cell aptoposis. Read more: Schmid,
D., G. E. Jarvis, F. Fay, D. M. Small, M. K. Greene, J. Majkut, S. Spence et
al. "Nanoencapsulation of ABT-737 and camptothecin enhances their clinical
potential through synergistic antitumor effects and reduction of systemic
toxicity." Cell death & disease 5, no. 10 (2014): e1454. http://www.nature.com/cddis/journal/v5/n10/full/cddis2014413a.html
“Abstract: The simultaneous
delivery of multiple cancer drugs in combination therapies to achieve optimal
therapeutic effects in patients can be challenging. This study investigated
whether co-encapsulation of the BH3-mimetic ABT-737 and the topoisomerase I
inhibitor camptothecin (CPT) in PEGylated polymeric nanoparticles (NPs) was a
viable strategy for overcoming their clinical limitations and to deliver both
compounds at optimal ratios. We found that thrombocytopenia induced by exposure
to ABT-737 was diminished through its encapsulation in NPs. Similarly,
CPT-associated leukopenia and gastrointestinal toxicity were reduced compared
with the administration of free CPT. In addition to the reduction of
dose-limiting side effects, the co-encapsulation of both anticancer compounds
in a single NP produced synergistic induction of apoptosis in both in vitro and
in vivo colorectal cancer models. This strategy may widen the therapeutic
window of these and other drugs and may enhance the clinical efficacy of
synergistic drug combinations.”
No comments:
Post a Comment